Cost-Effectiveness of Nirsevimab and Palivizumab for Respiratory Syncytial Virus Prophylaxis in Preterm Infants 29-34 6/7 Weeks' Gestation in the United States

• 2024

  Log in to bookmark this resource.

  Log in
• Tianzhou Yu; William Padula; Leah Yieh; Cynthia Gong
PMID: 37758594DOI: https://doi.org/10.1016/j.pedneo.2023.04.015

---

Access Resources

• Journal Article
• Ask aRCie About This Resource

About

This study compares the cost-effectiveness of two drugs, nirsevimab and palivizumab, used to prevent respiratory syncytial virus (RSV) in preterm infants born between 29 and 34 weeks' gestation in the United States. It describes how these medications help protect vulnerable babies from RSV, a common virus that can cause serious lung infections. The study looks at which drug provides better value for money while still keeping infants safe. By comparing costs and benefits, it helps doctors and parents make informed decisions about which treatment might be best for their children’s health.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Antiviral Agents; Cost-Benefit Analysis; Infant; Infant, Newborn; Pregnancy; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Palivizumab; Antibodies, Monoclonal, Humanized; Infant, Premature

Institutions: University of Southern California

---

More like this

Extending the Reach of Pediatric Emergency Preparedness: A Virtual Tabletop Exercise Targeting Children’s Needs 2019 · Centers for Disease Control and Prevention (CDC), University of Minnesota, University of Southern California Addressing Children's Needs in Disasters: A Regional Pediatric Tabletop Exercise 2018 · Boston Children's Hospital, Eastern Idaho Regional Medical Center, University of Southern California, Children's Hospital Los Angeles, Centers for Disease Control and Prevention (CDC) Postacute Sequelae of SARS-CoV-2 in Children 2024 · Children's Hospital Colorado, New York University, Children's Hospital Los Angeles, University of Southern California, Children's Hospital of Philadelphia, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Nemours Children's Health, Columbia University, Ann and Robert H. Lurie Children’s Hospital, University of California, San Diego

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---